A Phase 3 interventional study of Symbicort Turbuhaler (Budesonide/formoterol) and Drug: any available COPD treatment; investigator to decide in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 17 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2014-04-29.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 73rd largest by enrollment of the 194 interventional ones that give a count, is one of 25 that started in 2010, is one of 76 in phase 3, and was the 66th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in France
Ages 18–99
AstraZeneca · Sites in India
Ages 18+
AstraZeneca · Sites in Argentina, Egypt, Mexico and 4 more countries
Ages 18+
AstraZeneca · Sites in Argentina, Colombia, Egypt and 9 more countries
Ages 30–80
By country, each count listing its studies:
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 57 · Phase 3 77 · Phase 4 19
First in 1999; this study’s year is marked. 25 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 328 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 137 across the 194 interventional studies, 976 across the 89 observational. Of the 264 that completed or were terminated, 127 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
9 of the studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07315958AstraZenecaStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics | 2027-04-30 |
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
| NCT07307781AstraZenecaStudy of Patient With Frequent Exacerbations in Moscow | 2027-06-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of Symbicort Turbuhaler compared to standard COPD treatment during one year in Japanese patients with COPD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Symbicort Turbuhaler (Budesonide/formoterol)
Drug: Drug: any available COPD treatment; investigator to decide
Drug page: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol
2 x 160/4.5 microgram, inhalation, bid, 52 weeks
Also known as: Symbicort Turbuhaler
According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
Clinical Laboratory Test: Haematology -Erythrocytes
Mean change from Baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Haematology -Haemoglobin
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Haematology -Leucocytes
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Haematology -Platelet Count
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Haematology -Eosinophils
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Haematology -Basophils
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Haematology -Lymphocytes
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Haematology -Monocytes
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Haematology -Neutrophils
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Clinical Chemistry- S-Aspartate Aminotransferase
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Clinical Chemistry- S-Alkaline Phosphatase (ALP)
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Clinical Chemistry- S-Creatinine
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Clinical Chemistry- S-Total Bilirubin
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Clinical Chemistry- S-Sodium
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Clinical Chemistry- S-Potassium
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Clinical Chemistry- S- Calcium
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Clinical Chemistry- S-Albumin
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Clinical Chemistry- S-Protein, Total
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Clinical Chemistry- S-C-Reactive Protein
Change from baseline
Time frame: Baseline and 52 week after
Clinical Laboratory Test: Clinical Chemistry- S-Urea Nitrogen
Change from baseline
Time frame: Baseline and 52 week after
Vital Signs- Sitting Systolic Blood Pressure(SBP)
Change from baseline
Time frame: Baseline and 52 week after
Vital Signs- Sitting Diastolic Blood Pressure(DBP)
Change from baseline
Time frame: Baseline and 52 week after
Vital Signs- Pulse Rate
Change from baseline
Time frame: Baseline and 52 week after
ECG Variables - Heart Rate
Change from baseline
Time frame: Baseline and 52 week after
ECG Variables - QT Interval
Change from baseline
Time frame: Baseline and 52 week after
ECG Variables - QTcB Interval
Change from baseline
Time frame: Baseline and 52 week after
ECG Variables - QTcF Interval
Change from baseline
Time frame: Baseline and 52 week after
ECG Variables - RR Interval
Change from baseline
Time frame: Baseline and 52 week after
Chronic Obstructive Pulmonary Disease (COPD) symptoms_Night-time Awakening
There are 5 alternatives (scored 0 to 4, 0= no awakening and 4 =did not sleep at all). The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period and daily during 52-week randomization treatment
Chronic Obstructive Pulmonary Disease (COPD) symptoms_Breathlessness
There are 5 alternatives (scored 0 to 4, 0= unaware of any difficulty and 4 =almost constant, present even when resting). The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period and daily during 52-week randomization treatment
Chronic Obstructive Pulmonary Disease (COPD) symptoms_cough
There are 5 alternatives (scored 0 to 4, 0= unaware of coughing, 4= never free of cough or need to cough). The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period and daily during 52-week randomization treatment
Forced Expiratory Volume in 1 Second (FEV1) Measured With the Spirometer at the Clinic
The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.
Time frame: Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization
Forced Vital Capacity (FVC) Measured With the Spirometer at the Clinic
The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.
Time frame: Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization
Time to First COPD Exacerbation
A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.
Time frame: Daily during 52-week randomization treatment
Number of COPD Exacerbations Over the Study Treatment Period
A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment
Time frame: Daily during 52-week randomization treatment
Rescue Medication Use
The change from run-in period and daily during 52-week randomization treatment
Time frame: Daily during 52-week randomization treatment
Health Related Quality of Life (HRQL) Based on the St. George's Respiratory Questionnaire (SGRQ)
The change from run-in period and daily during 52-week randomization treatment average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).
Time frame: Daily during run-in period and daily 52-week randomization treatment
Morning Peak Expiratory Flow (PEF) Measured at Home
The change from Run-in period average to 52-week randomization Treatment period average for each treatment group
Time frame: Daily during run-in period and daily 52-week randomization treatment
Evening Peak Expiratory Flow (PEF) Measured at Home
The change from Run-in period average to 52-week randomization Treatment period average for each treatment group
Time frame: Daily during run-in period and daily 52-week randomization treatment
Morning FEV1 Measured by the Subjects at Home
The change from run-in period and daily during 52-week randomization treatment
Time frame: Daily during run-in period and daily 52-week randomization treatment
Evening FEV1 Measured by the Subjects at Home
The change from run-in period and daily during 52-week randomization treatment
Time frame: Daily during run-in period and daily 52-week randomization treatment
The first participant entered the study on 28 January 2010, and the last participant completed the study on 24 October 2011. A total of 328 participants were enrolled at 60 centres in Japan, and 260 participants who fulfilled the randomisation criteria were randomised.
| Milestone | Symbicort Turbuhaler | COPD Standard Therapy |
|---|---|---|
| Started | 130 | 130 |
| Completed | 110 | 112 |
| Not completed | 20 | 18 |
| Withdrew: Withdrawal by subject | 6 | 9 |
| Withdrew: Adverse event | 14 | 9 |
Mean change from Baseline
| *10000/μl | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Haematology -Erythrocytes | -7.6 ± 23.9 | -0.1 ± 22.9 |
Change from baseline
| g/dL | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Haematology -Haemoglobin | -0.22 ± 0.74 | -0.05 ± 0.75 |
Change from baseline
| /microliter(mcl) | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Haematology -Leucocytes | 160.8 ± 1704.0 | -184.8 ± 1238.2 |
Change from baseline
| *10000/μl | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Haematology -Platelet Count | 0.86 ± 3.03 | 0.12 ± 4.04 |
Change from baseline
| percentage of Eosinophils | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Haematology -Eosinophils | -0.52 ± 2.68 | 0.14 ± 1.91 |
Change from baseline
| percentage of Basophils | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Haematology -Basophils | -0.06 ± 0.37 | -0.06 ± 0.35 |
Change from baseline
| percentage of Lymphocytes | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Haematology -Lymphocytes | -5.47 ± 6.56 | -3.24 ± 7.00 |
Change from baseline
| percentage of Monocytes | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Haematology -Monocytes | 0.29 ± 1.41 | -0.03 ± 1.35 |
Change from baseline
| percentage of Neutrophils | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Haematology -Neutrophils | 5.78 ± 7.16 | 2.92 ± 7.64 |
Change from baseline
| U/L | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase | 0.5 ± 7.6 | 1.5 ± 6.6 |
Change from baseline
| U/L | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry- S-Aspartate Aminotransferase | 0.0 ± 7.6 | 1.1 ± 6.5 |
Change from baseline
| U/L | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry- S-Alkaline Phosphatase (ALP) | 1.3 ± 38.4 | 8.2 ± 45.9 |
Change from baseline
| mg/dL | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry- S-Creatinine | 0.003 ± 0.106 | -0.017 ± 0.091 |
Change from baseline
| mg/dL | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry- S-Total Bilirubin | 0.05 ± 0.25 | 0.00 ± 0.18 |
Change from baseline
| mEq/L | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry- S-Sodium | -0.8 ± 2.0 | -0.6 ± 1.7 |
Change from baseline
| mEq/L | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry- S-Potassium | -0.11 ± 0.34 | -0.08 ± 0.37 |
Change from baseline
| mg/dL | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry- S- Calcium | 0.02 ± 0.34 | 0.01 ± 0.33 |
Change from baseline
| g/dL | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry- S-Albumin | 0.03 ± 0.24 | 0.04 ± 0.26 |
Change from baseline
| g/dL | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry- S-Protein, Total | 0.01 ± 0.35 | 0.02 ± 0.37 |
Change from baseline
| mg/dL | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry- S-C-Reactive Protein | 0.243 ± 1.291 | 0.224 ± 1.423 |
Change from baseline
| mg/dL | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry- S-Urea Nitrogen | -0.51 ± 4.09 | -0.64 ± 3.32 |
Change from baseline
| mmHg | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Vital Signs- Sitting Systolic Blood Pressure(SBP) | -0.8 ± 16.2 | -3.2 ± 15.0 |
Change from baseline
| mmHg | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Vital Signs- Sitting Diastolic Blood Pressure(DBP) | -0.8 ± 11.2 | -1.3 ± 10.7 |
Change from baseline
| beats/minute | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Vital Signs- Pulse Rate | 3.2 ± 11.1 | 3.1 ± 11.5 |
Change from baseline
| beats/minute | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| ECG Variables - Heart Rate | 3.6 ± 11.4 | 3.4 ± 10.9 |
Change from baseline
| ms | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| ECG Variables - QT Interval | -4.5 ± 23.1 | -7.5 ± 21.2 |
Change from baseline
| ms | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| ECG Variables - QTcB Interval | 3.6 ± 20.9 | 2.4 ± 22.6 |
Change from baseline
| ms | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| ECG Variables - QTcF Interval | 0.7 ± 16.3 | -1.1 ± 17.4 |
Change from baseline
| ms | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| ECG Variables - RR Interval | -30.9 ± 121.4 | -43.8 ± 115.1 |
There are 5 alternatives (scored 0 to 4, 0= no awakening and 4 =did not sleep at all). The change from Run-in period average to Treatment period average for each treatment group
| units on a scale | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Chronic Obstructive Pulmonary Disease (COPD) symptoms_Night-time Awakening | 0.0 ± 0.5 | -0.1 ± 0.4 |
There are 5 alternatives (scored 0 to 4, 0= unaware of any difficulty and 4 =almost constant, present even when resting). The change from Run-in period average to Treatment period average for each treatment group
| units on a scale | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Chronic Obstructive Pulmonary Disease (COPD) symptoms_Breathlessness | -0.2 ± 0.7 | -0.1 ± 0.7 |
There are 5 alternatives (scored 0 to 4, 0= unaware of coughing, 4= never free of cough or need to cough). The change from Run-in period average to Treatment period average for each treatment group
| units on a scale | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Chronic Obstructive Pulmonary Disease (COPD) symptoms_cough | -0.2 ± 0.7 | -0.2 ± 0.7 |
The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.
| percentage of Baseline | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Forced Expiratory Volume in 1 Second (FEV1) Measured With the Spirometer at the Clinic | 104.25 (60.8 to 182.9) | 98.43 (35.8 to 168.2) |
The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.
| percentage of Baseline | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Forced Vital Capacity (FVC) Measured With the Spirometer at the Clinic | 102.51 (77.8 to 141.5) | 100.04 (67.6 to 158.2) |
A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.
| Percentage of participants | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Time to First COPD Exacerbation | 20.0 | 31.5 |
A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment
| event | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Number of COPD Exacerbations Over the Study Treatment Period | 41 | 105 |
The change from run-in period and daily during 52-week randomization treatment
| innhalation/day | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Rescue Medication Use | -0.2 ± 1.0 | 0.0 ± 1.4 |
The change from run-in period and daily during 52-week randomization treatment average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).
| units on a scale | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Health Related Quality of Life (HRQL) Based on the St. George's Respiratory Questionnaire (SGRQ) | -2.03 ± 8.56 | -0.42 ± 7.47 |
The change from Run-in period average to 52-week randomization Treatment period average for each treatment group
| Liter/minute(L/min) | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Morning Peak Expiratory Flow (PEF) Measured at Home | 5.9 ± 31.8 | 5.7 ± 30.9 |
The change from Run-in period average to 52-week randomization Treatment period average for each treatment group
| Liter/minute(L/min) | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Evening Peak Expiratory Flow (PEF) Measured at Home | 2.7 ± 30.0 | 5.2 ± 29.3 |
The change from run-in period and daily during 52-week randomization treatment
| Liter(L) | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Morning FEV1 Measured by the Subjects at Home | 0.017 ± 0.147 | 0.006 ± 0.171 |
The change from run-in period and daily during 52-week randomization treatment
| Liter(L) | Arm 1 - Symbicort Turbuhaler | Arm 2 - COPD Standard Therapy |
|---|---|---|
| Evening FEV1 Measured by the Subjects at Home | 0.006 ± 0.142 | 0.010 ± 0.156 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Symbicort Turbuhaler | — | 25/130 (19.2%) | 75/130 (57.7%) |
| COPD Standard Therapy | — | 34/130 (26.2%) | 72/130 (55.4%) |
| Event | Symbicort Turbuhaler | COPD Standard Therapy |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 8/130 | 20/130 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 6/130 | 5/130 |
| Pneumonia BacterialRespiratory, thoracic and mediastinal disorders | 0/130 | 5/130 |
| CataractRespiratory, thoracic and mediastinal disorders | 0/130 | 2/130 |
| Cerebral InfarctionRespiratory, thoracic and mediastinal disorders | 2/130 | 0/130 |
| Lung Neoplasm MalignantRespiratory, thoracic and mediastinal disorders | 2/130 | 1/130 |
| Pulmonary TuberculosisRespiratory, thoracic and mediastinal disorders | 0/130 | 2/130 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 1/130 | 2/130 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/130 | 0/130 |
| Arteriosclerosis ObliteransRespiratory, thoracic and mediastinal disorders | 0/130 | 1/130 |
| Event | Symbicort Turbuhaler | COPD Standard Therapy |
|---|---|---|
| NasopharyngitisInfections and infestations | 55/130 | 51/130 |
| BronchitisInfections and infestations | 15/130 | 13/130 |
| ConstipationGastrointestinal disorders | 10/130 | 13/130 |
| Back PainMusculoskeletal and connective tissue disorders | 6/130 | 10/130 |
| PneumoniaInfections and infestations | 9/130 | 3/130 |
| PharyngitisInfections and infestations | 9/130 | 3/130 |
| InsomniaPsychiatric disorders | 7/130 | 1/130 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 7/130 | 1/130 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 7/130 | 7/130 |
| Age, Continuous(Years) | Symbicort Turbuhaler | COPD Standard Therapy | Total |
|---|---|---|---|
| Mean | 70.1 (40 to 87) | 71.5 (54 to 85) | 70.8 (40 to 87) |
| Sex: Female, Male(Participants) | Symbicort Turbuhaler | COPD Standard Therapy | Total |
|---|---|---|---|
| Female | 5 | 4 | 9 |
| Male | 125 | 126 | 251 |
The record gives a start of Jan 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol
Pulmonary Disease, Chronic Obstructive →